The incidence of hypersensitivity pneumonitis (HP) is lower in smokers than in non smokers. Since nicotine is immunosuppressive, we hypothetized that it could have a protective effect on HP induction in vivo. HP was induced in mice which were treated with nicotine either intraperitoneally (IP) (0.5 to 2.0 mg/kg/day) or intranasally ( 
Introduction
Nicotine, a tertiary cholinomimetic alkaloid, is a major component of cigarette smoke. This molecule is highly lipophylic and thus has the capacity to cross the blood/brain barrier and cause addiction 1 . This nicotinic agonist has some immunomodulatory and anti-fibrotic effects. In fact, it inhibits lymphocyte proliferation 2 ,
interleukin-1 (IL-1 ), tumor necrosis factor (TNF), IL-6 and IL-12 production by macrophages 3 4 , the expression of co-stimulatory molecules such as CD28 and CTLA-4 on T cells 5 , and fibroblast proliferation 6 . Nicotine is effective in the treatment of ulcerative colitis, an intestinal inflammatory disease 7 , and has been shown to have beneficial effects in a type 1 diabetes mouse model 8 .
Interestingly, certain inflammatory diseases such as sarcoidosis and ulcerative colitis are less frequent in smokers than in non-smokers, and cigarette smoking protects against radiation pneumonitis 9, 10 . When exposed to an environment that can cause hypersensitivity pneumonitis (HP), smokers have lower levels of specific antibodies to 4 molecules or CD80-86) plays a major role in the development of this disease: blockade of this pathway inhibits the inflammatory response to SR antigen in mice 15 . Cytokines such as TNF, IFN-and IL-10 are involved in HP. Increased TNF serum bioactivity was reported in farmer's lung patients 16 . Animal models have also shown that IL-10 modulates inflammation and IFN-is necessary for development of the disease 17;18 .
Generally, smokers have lung inflammation characterized by an increased number of AM (up to 99% of total cells) as demonstrated by bronchoalveolar lavage (BAL) 19 .
The aim of this study was to verify if nicotine could, at least in part, be responsible for the protection against the development of HP observed in smokers, and look at possible mechanisms of action. For this, we used a previously described mouse model of HP that has been used extensively in our laboratory 15 and treated mice with nicotine, either
intraperitoneally (IP) or intranasally (IN).
In addition, an AM cell line stimulated with SR antigen or E. Coli lipopolysaccharide (LPS), a potent activator of AM 3 , was used to test the effect of nicotine on TNF, IFN-and IL-10 mRNA expression and B7 co-stimulatory molecule expression in vitro. Some of the results in these studies have been previously published in the form of an abstract 
Material and methods

Induction of HP and BAL
Histopathological studies
A section of the left lung from the highest nicotine dose (2.0mg/kg) IN treated mice from a separate group that did not undergo BAL was collected on the day of the sacrifice and stained with hematoxilin/eosin. Inflammatory parameters of the lung tissue were evaluated blindly by a pathologist. Histology score was graded from 0 to 4.
Semi-quantitative cytokine mRNA expression
The RT-PCR experiments were done on lung sections (from the 2.0mg/kg IN treated group) lysed in TRIZOL reagent (Gibco BRL). Total RNA was extracted and quantified with Ribo-Green reagent (Molecular Probes). One µg RNA was reverse transcribed with MMLV-Reverse Transcriptase (Gibco BRL) and a polymerase chain reaction (PCR) was performed with a Peltier Thermal Cycler 200 for detection of IFN-and IL-10 mRNA expression using Taq DNA polymerase (Promega). Primers used for IFN-and IL-10 were from Biosource International (Québec, Canada).
The PCR reaction was run on a 1,5% agarose gel, stained with ethidium bromide and exposed to UV light. Densitometric analyses of the bands were performed (ScionImage) .
In vitro studies
A mouse AM cell line, AMJ2-C11 (ATCC), was used. Cells (150 000) were plated in a 24 well plate, stimulated with SR (50µg/ml) or LPS (0.1µg/ml) for 24 hours and treated with 0, 40, 80 or 160 µM nicotine. Supernatants TNF levels were measured by enzyme-linked immunosorbant assay (ELISA); (RD Diagnostics) and cells were collected for analysis of the B-7 (CD80/86) costimulatory molecule expression or lysed using TRIZOL reagent (Gibco BRL) for RNA extraction.
Semi-quantitative RT-PCR for in vitro studies
Cell lysis, RNA extraction, quantification and RT-PCR were performed as for the in vivo studies. Primers used for TNF were : 3'-CCT GGC TAG TGG GGC TTC AAG TCA TCT GTC TT -5' and 5'-GTA TGA GAT AGC AAA TCG GCT GAC GGT GTG GG -3'. Primers used for IFN-and IL-10 were the same as for the in vivo studies.
Flow cytometry analysis for CD80/86 expression
Cells were stimulated with LPS or SR ,treated with 40µM nicotine for 24 hours and incubated for 45 minutes with a mouse anti-CD80 antibody coupled to FITC fluorochrome or a mouse anti-CD86 coupled to PE fluorochrome, or their isotype control.
The percentage of cells positive for CD80/86 was analysed in an Epics ELITE flow cytometer.
Statistical analysis
Statistical analysis was made using an ANOVA table followed by a Fisher's posthoc test.
Results
Total cell and differential counts in BAL
Results of BAL total cell counts and differential counts are presented in figures 1 , 
RT-PCR for in vivo studies
The results for RT-PCR for detection of IFN-and IL-10 mRNA expression in mice lung sections from the highest dose treated mice (2.0 mg/kg) are presented in figure   5 . The ratio between the intensity of the -actin band and that of the cytokine band was 
TNF concentration in AMJ2-C11 cell line supernatants (in vitro studies)
Results on the effect of nicotine on TNF levels in LPS and SR stimulated AMJ2-C11 cells supernatants are presented in figure 6 . Results are expressed as a percentage of release, 100% being attributed to LPS or SR stimulated and untreated cells. The TNF release was significantly reduced to 84% for 160µM nicotine treated and LPS stimulated cells (figure 6A) (n = 4; p= 0.004). Similarly, TNF release was significantly reduced to 76% for 160 µM nicotine treated and SR stimulated cells (figure 6B) (n = 4; p = 0.02).
AMJ2-C11 cells failed to release IL-10 and IFN-(data not shown).
Flow cytometry analysis
In the AMJ2-C11 cell line, CD86 was expressed in 100% of the cells; no stimulation of expression was therefore achievable by LPS or SR. Nicotine had no effect on CD86 expression. CD80 was expressed in 5% of unstimulated cells. 
RT-PCR for in vitro studies (AMJ2-C11 cell line)
Results further studies will be needed in order to identify the optimal anti-inflammatory dose.
Similar results with low doses of nicotine being more effective to reduce inflammation than high concentrations have also been reported in treatment of ulcerative colitis 24 .
The effect of nicotine on tissue infiltration of inflammatory cells further supports the anti-inflammatory effects of nicotine.
One of the reasons we used IN administration was to avoid the liver first pass effect and to achieve an anti-inflammatory effect at lower doses than with IP administration. When administered intranasally (IN), nicotine is rapidly absorbed by the vessels surrounding the nasal sinuses. These vessels drain into the superior vena cava, and blood passes into pulmonary circulation before entering the peripheral circulation 22 .
Our research supports the better effect of direct administration into the lungs compared to systemic administration; the 0.025 mg/kg dose administered IN had a significant antiinflammatory effect while the 0.25 mg/kg dose administered IP did not. The inhibitory effect of nicotine on CD80 expression on the mouse AM cell line suggests that AM could be at least partially responsible for the observed lymphocyte suppression. Since blockade of the CD80/86-CTLA-4/CD28 pathway inhibits lymphocyte response to SR antigen 15 , the decrease in expression of CD80 that we observed could be another mechanism by which cigarette smoking could decrease the risk for HP.
TNF is a cytokine that is involved in the pathology of HP 16 Since nicotine did reduce IL-10 mRNA production by AM in vitro, the expression found in lung tissue from the mouse lungs could come from other inflammatory cells or from structural cells.
The inhibitory effect of nicotine could not only explain the lower prevalence of HP in smokers, but also the different outcome of HP that does occur in some smokers 12 .
The down regulating effect could be sufficient to prevent acute HP. Subjects could thus develop a more insidious form that could progress to irreversible lung damage before the diagnosis is made, explaining the poorer outcome in these subjects.
Lymphocytes are highly activated and recruited by the cytokines released by AM.
The inhibitory effect of nicotine on cytokines mRNA production in AM could, together with inhibition of the co-stimulatory pathway, explain the decrease in the lymphocyte population in the BAL of nicotine treated animals. We are aware that inhibition of mRNA expression does not always transfer to a protein production inhibition, but however, there was concordance between TNF mRNA levels and protein release in AMJ2-C11 cells. Since in our study the decrease in mRNA and protein expression corresponds to cellular findings, we believe that the overall inhibitory effect of nicotine could explain, at least to some extent, the protection that smokers have against the development of this disease.
Conclusion
Results of this study show that nicotine reduces the alveolar inflammatory response to SR antigen and affects some AM (stimulated with LPS or SR) functions in vitro. This influence could be, at least in part, responsible for the protection that smokers have against development of HP. Since nicotine is effective in the treatment of ulcerative colitis, it could also be of interest in the treatment of HP and other pulmonary inflammatory diseases. 
